FDA approves CSL Behring rare disease treatment
The Food and Drug Administration granted marketing clearance Friday for Hizentra, a treatment for chronic inflammatory demyelinating polyneuropathy developed by CSL Behring. Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune disorder that affects the peripheral nerves and may cause permanent nerve damage. The condition, which afflicts an estimated 40,000 people in the United States, can cause nerve numbness or tingling, muscle weakness, fa tigue and other symptoms. An… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 16, 2018 Category: Biotechnology Authors: John George Source Type: news

FDA Approves Hizentra(R) (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
First and only subcutaneous immunoglobulin (SCIg) approved for the treatment of CIDP based on the largest controlled clinical study in CIDP KING OF PRUSSIA, Pa., March 16, 2018 -- (Healthcare Sales & Marketing Network) -- Global biotherapeutics leader ... Biopharmaceuticals, FDA CSL Behring, Hizentra, Immune Globulin, CIDP (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 16, 2018 Category: Pharmaceuticals Source Type: news

EU Clears First Subcutaneous Immunoglobulin (Hizentra) for CIDP EU Clears First Subcutaneous Immunoglobulin (Hizentra) for CIDP
Hizentra is the first subcutaneous immunoglobulin approved as maintenance therapy to prevent relapse of neuromuscular disability and impairment in chronic inflammatory demyelinating polyneuropathy.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 15, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news

Medical News Today: What to know about CIDP
A look at chronic inflammatory demyelinating polyneuropathy (CIDP), a condition where that causes nerve damage. Included is detail on treatment. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 25, 2018 Category: Consumer Health News Tags: Neurology / Neuroscience Source Type: news

Subcutaneous Immunoglobulin Effective for Maintenance in CIDP Subcutaneous Immunoglobulin Effective for Maintenance in CIDP
Subcutaneous immunoglobulin is effective and convenient maintenance therapy for chronic inflammatory demyelinating polyneuropathy, the PATH trial has shown. Local reactions decreased with repeat dosing.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 19, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

CSL Behring Announces FDA Approval of Privigen [Immune Globulin Intravenous (Human), 10% Liquid] for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Adults
KING OF PRUSSIA, Pa. — 14 September 2017 -- Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved Privigen® [Immune Globulin Intravenous (Human), 10% Liquid] for the treatment of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 14, 2017 Category: Drugs & Pharmacology Source Type: news

5 Moving Stories Of Pets That Helped Their Humans Through Tough Times
A large body of research shows that having a pet is, quite simply, good for a person. Pet ownership has been linked to physical and psychological benefits including lowered blood pressure, decreased stress and greater emotional well-being. But, for some, having a pet in their lives means even more; it can be a transformative experience. We partnered with PEDIGREE® to tell five stories that highlight the incredible difference a pet can make in a person’s life.   Chaton Fife has a neurological disorder with a big name: Chronic Inflammatory Demyelinating Polyneuropathy. But, remarkably, it’s a tiny dog n...
Source: Healthy Living - The Huffington Post - May 12, 2016 Category: Consumer Health News Source Type: news

IVIG + corticosteroids good value for money in CIDP in Thailand
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 30, 2016 Category: Drugs & Pharmacology Source Type: news

How Common Is CIDP Misdiagnosis?How Common Is CIDP Misdiagnosis?
Dr Barclay reviews the results of a study exploring the diagnostic pitfalls of chronic inflammatory demyelinating polyneuropathy. Medscape Neurology (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 29, 2015 Category: Neurology Tags: Neurology & Neurosurgery Viewpoint Source Type: news

Pfizer receives orphan drug status for GL-2045 to treat CIDP
Pfizer has received orphan drug designation from the US Food and Drug Administration (FDA) for the autoimmune candidate GL-2045. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 10, 2015 Category: Pharmaceuticals Source Type: news

Your Mysterious Nerve Pain Could Be Undiagnosed Celiac Disease, According To New Study
People with celiac disease are more than twice as likely to suffer from nerve damage than the general population, according to a recently published study in the medical journal JAMA Neurology. The association is so strong that the study authors suggest people with nerve damage should also be screened for celiac disorder in order to pinpoint potential treatment options, according to lead researcher Jonas Ludvigsson of the Swedish medical university Karolinska Institutet. "The current guidelines suggest that patients with neuropathy [nerve pain] should be screened for type 1 diabetes and certain vitamin deficiencies,...
Source: Science - The Huffington Post - May 15, 2015 Category: Science Source Type: news

Early Identification of 'Acute-Onset' Chronic IDPEarly Identification of 'Acute-Onset' Chronic IDP
The authors identify changes in nerve excitability parameters that can distinguish acute-onset chronic inflammatory demyelinating polyneuropathy from acute IDP at the earliest stages. Brain (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 8, 2014 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Immunoglobulin Market (PI & CIDP ) Analysis and Forecasts to 2019...
“Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) potentially supplemented by approvals for Alzheimers disease” is...(PRWeb May 27, 2013)Read the full story at http://www.prweb.com/releases/immunoglobulin-market/pi-cidp-analysis-2019/prweb10772086.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 29, 2013 Category: Pharmaceuticals Source Type: news

CHMP recommends approval of Privigen® (human normal immunoglobulin) for chronic inflammatory demyelinating polyneuropathy
Source: European Medicines Agency Area: News The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended a variation to the terms of the marketing authorisation for Privigen® (human normal immunoglobulin). The CHMP recommends the adoption of a new indication: the treatment of adults, and children and adolescents (0-18 years) with chronic inflammatory demyelinating polyneuropathy (CIDP).  Only limited experience is available of use of intravenous immunoglobulins in children with CIDP.   Detailed recommendations for the use of this product will be described i...
Source: NeLM - News - February 25, 2013 Category: Drugs & Pharmacology Source Type: news